Overexpression of p101 activates PI3Kγ signaling in T cells and contributes to cell survival

Oncogene

Volumn 26, Issue 49, 2007, Pages 7049-7057

  Johnson, C ^a   Marriott, S J ^b   Levy, L S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Lymphoma; Phosphatidylinositol 3 kinase gamma; Retrovirus integration site

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P101; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STOICHIOMETRY; T CELL LYMPHOMA; T LYMPHOCYTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; BACTERIAL PROTEINS; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; ISOENZYMES; JURKAT CELLS; LUMINESCENT PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; ULTRAVIOLET RAYS;

GAMMARETROVIRUS; MUS;

EID: 35548991099     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210504     Document Type: Article

References (31)

1. Abdel-Mageed A, Agrawal KC. (1997). Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 4: 199-207.
2. Bader AG, Kang S, Vogt PK. (2006). Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103: 1475-1479.
3. Brock C, Schaefer M, Reusch HP, Czupalla C, Michalke M, Spicher K et al. (2003). Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. J Cell Biol 160: 89-99.
4. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG et al. (1997). Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997-5000.
5. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS et al. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
6. Curnock AP, Logan MK, Ward SG. (2002). Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 105: 125-136.
7. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR. (2002). Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. J Biol Chem 277: 37124-37130.
8. Freeburn RW, Wright KL, Burgess SJ, Astoul E, Cantrell DA, Ward SG. (2002). Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J Immunol 169: 5441-5450.
9. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L et al. (2004). Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64: 3014-3021.
10. Grandori C, Cowley SM, James LP, Eisenman RN. (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699.
11. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
12. Hickey FB, Cotter TG. (2006). BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J Biol Chem 281: 2441-2450.
13. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L et al. (2000). Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287: 1049-1053.
14. Jimenez C, Jones DR, Rodriguez-Viciana P, Gonzalez-Garcia A, Leonardo E, Wennstrom S et al. (1998). Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17: 743-753.
15. Johnson C, Lobelle-Rich PA, Puetter A, Levy LS. (2005). Substitution of feline leukemia virus long terminal repeat sequences into murine leukemia virus alters the pattern of insertional activation and identifies new common insertion sites. J Virol 79: 57-66.
16. Jucker M, Sudel K, Horn S, Sickel M, Wegner W, Fiedler W et al. (2002). Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 16: 894-901.
17. Kang S, Bader AG, Zhao L, Vogt PK. (2005). Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4: 578-581.
18. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. (2006). Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 103: 1289-1294.
19. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH et al. (2004). PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 112: 407-410.
20. Okkenhaug K, Vanhaesebroeck B. (2003). PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3: 317-330.
21. Samuels Y, Velculescu VE. (2004). Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3: 1221-1224.
22. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B et al. (2000). Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287: 1040-1046.
23. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C et al. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102.
24. Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis PC, Hawkins PT. (1994). A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 77: 83-93.
25. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J et al. (1997). The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89: 105-114.
26. Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P, Stephens L. (2005). p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr Biol 15: 566-570.
27. Vanhaesebroeck B, Alessi DR. (2000). The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346: 561-576.
28. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ et al. (1997). P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 94: 4330-4335.
29. Voigt P, Brock C, Nurnberg B, Schaefer M. (2005). Assigning functional domains within the p101 regulatory subunit of phosphoinositide 3-kinase gamma. J Biol Chem 280: 5121-5127.
30. Voigt P, Dorner MB, Schaefer M. (2006). Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J Biol Chem 281: 9977-9986.
31. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T et al. (2002). Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 198: 335-342.